This document reports on a study examining the use of mycophenolate mofetil (MMF) for treating primary glomerulonephritis. Four patients with focal segmental glomerulosclerosis (FSGS) or membranous nephropathy received MMF for at least 6 months. Results showed reduced urine protein levels and improved or stable kidney function in most patients, suggesting MMF may be useful for treating these conditions. However, larger randomized controlled trials are still needed to validate MMF's efficacy.